Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

March 23, 2017

Phase 2 Trial of TG4010, Opdivo Combo for NSCLC Gets Underway

News

A Phase 2 trial evaluating the cancer vaccine TG4010 in combination with Opdivo (nivolumab) in metastatic non-small cell lung cancer (NSCLC) patients who failed one prior line of platinum-based chemotherapy has ... Read more

March 21, 2017

Lung Cancer Is Underdiagnosed in Metastatic Kidney Cancer Patients, Study Suggests

News

Patients with kidney cancer that has spread to the lungs may develop a separate lung cancer that is easily overlooked, according to a study. The danger is that lung cancer ... Read more

March 14, 2017

Statins Don’t Help Small-cell Lung Cancer Patients Who Get Chemotherapy, Study Suggests

News

Using cholesterol-lowering drugs in combination with chemotherapy does not improve the outcomes of patients with small-cell lung cancer, according to results from the largest randomized trial ever of statin therapy in ... Read more

March 9, 2017

Nasal Swab Could Identify Smokers with Lung Lesions at Risk of Having Lung Cancer

News

A simple nasal swab in patients suspected of having lung disease may have the potential to distinguish between benign and malignant lung lesions, according to a recent study by the Boston University ... Read more

March 7, 2017

UK’s NICE Rejects Keytruda as First-line Therapy for Certain NSCLC Patients

News

The immune checkpoint inhibitor Keytruda (pembrolizumab) had received European Union approval last December as first-line therapy for patients with non-small cell lung cancer who have PD-L1 expression in at least ... Read more

February 28, 2017March 1, 2017

Novocure Enrolls First Lung Cancer Patient in Trial with Electric-therapy Component

News

Novocure has enrolled the first patient in a trial to assess the use of its electric-stimulation technology in conjunction with standard therapies to treat lung cancer patients who failed to respond to ... Read more

February 23, 2017

European Commission Approves ALK Inhibitor Alecensa for Some Lung Cancer Patients

News

The European Commission has conditionally authorized F. Hoffmann-La Roche to market the ALK inhibitor Alecensa (alectinib hydrochloride) for treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who are intolerant ... Read more

February 16, 2017

ARIAD Seeks European Authorization of Brigatinib as Lung Cancer Treatment

News

ARIAD Pharmaceuticals has asked the European Union to approve the marketing of its investigational therapy brigatinib for lung cancer. The European Medicines Agency (EMA) will recommend whether the EU should ... Read more

February 2, 2017February 2, 2017

Keytruda Approved in EU for Previously Untreated Metastatic NSCLC Patients

News

The European Commission has approved Keytruda (pembrolizumab) for previously untreated metastatic non-small cell lung cancer (NSCLC) patients who have high PD-L1 expression and no EGFR or ALK mutations. It can ... Read more

January 24, 2017

Delayed Chemotherapy After Surgery May Still Benefit NSCLC Patients

News

Non-small-cell lung cancer (NSCLC) patients who recover slowly from surgery may still benefit from post-operative, or adjuvant, chemotherapy, even if it is delayed up to four months, researchers said in a study ... Read more